Bringing the Oncology Community Together
Anderson Provides Insight Into Novel Agents in Multiple Myeloma
The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval.
To Succeed, Urology Practices Must Change With the Times
Entrepreneur James Feldman, chief innovation officer of the Chicago-based company Shift Happens!, calls himself “a doctor for business.”
FDA Extends Panobinostat Review Period for Multiple Myeloma
The FDA has extended the review period for panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone for patients with previously treated multiple myeloma by 3 months, placing a new decision date in early 2015.
Government Come to Call? How to Protect Your Practice
Urologists hear quite a bit about risk from the legislative and regulatory angles.
Pfizer, Merck KGaA Collaboration Accelerates PD-L1 Inhibitor Development
Pfizer and Merck KGaA have agreed to collaborate on the development of the PD-L1 inhibitor MSB0010718C as a potential treatment for multiple types of cancer.
Juno CAR T Cell Therapy Receives Breakthrough Designation for ALL
The chimeric antigen receptor (CAR) T cell therapy JCAR015 has received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
FDA Grants Orphan Drug Designation to BGB324 for AML
The FDA has granted an orphan drug designation to the novel AXL inhibitor BGB324 (R428) for the treatment of patients with acute myeloid leukemia (AML).
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.